Back to Search Start Over

Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID‐19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic.

Authors :
Kikuchi, Kan
Nangaku, Masaomi
Ryuzaki, Munekazu
Yamakawa, Tomoyuki
Ota, Yoshihiro
Hanafusa, Norio
Sakai, Ken
Kanno, Yoshihiko
Ando, Ryoichi
Shinoda, Toshio
Wakino, Shu
Nakamoto, Hidetomo
Takemoto, Yoshiaki
Akizawa, Tadao
Source :
Therapeutic Apheresis & Dialysis; Dec2023, Vol. 27 Issue 6, p1064-1069, 6p
Publication Year :
2023

Abstract

Introduction: In the present study, the efficacy of sotrovimab and molnupiravir in dialysis patients with COVID‐19 was investigated using a registry of COVID‐19 in Japanese dialysis patients. Methods: Dialysis patients with confirmed SARS‐CoV‐2 during the COVID‐19 (Omicron BA.1 and BA.2) pandemic were analyzed. Patients were classified into four treatment groups: molnupiravir monotherapy (molnupiravir group), sotrovimab monotherapy (sotrovimab group), molnupiravir and sotrovimab combination therapy (combination group), and no antiviral therapy (control group). The mortality rates in the four groups were compared. Results: A total of 1480 patients were included. The mortality of the molnupiravir, sotrovimab, and combination groups were significantly improved compared to the control group (p < 0.001). Multivariate analysis indicated that antiviral therapy improves the survival of dialysis patients with COVID‐19 (hazard ratio was 0.184 for molnupiravir, 0.389 for sotrovimab, and 0.254 for combination groups, respectively). Conclusion: Sotrovimab showed efficacy in Omicron BA.1 but attenuated in BA.2. Molnupiravir also showed efficacy in BA.2, suggesting administration of molnupiravir would be important. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17449979
Volume :
27
Issue :
6
Database :
Complementary Index
Journal :
Therapeutic Apheresis & Dialysis
Publication Type :
Academic Journal
Accession number :
173398136
Full Text :
https://doi.org/10.1111/1744-9987.14033